In preclinical studies, glucose transporter (GLUT) inhibitors have been shown to induce disulfidptosis in SLC7A11-overexpressing cancer cells, effectively suppressing tumor growth while minimizing toxicity to healthy tissues (14). The gene discussed is SLC2A1; the disease is cancer.